Colotect 1.0™ colorectal cancer test
A non-invasive methylation test that enables early detection of colorectal cancer or precancerous changes. Performed at home, it evaluates DNA changes associated with the presence of tumour cells.
Early diagnosis can save a life
Colorectal cancer is one of the most common cancers in Lithuania and claims hundreds of lives every year. The disease often develops without clear symptoms, so it is frequently diagnosed late. Early detection is one of the most important factors influencing treatment success and survival. The modern Colotect 1.0 methylation test allows patients to conveniently assess risk at home and take action before symptoms appear.
How does the Colotect 1.0 test work?
Colotect 1.0 is a non-invasive colorectal cancer test based on advanced methylation analysis technology. The test evaluates specific DNA methylation changes that occur in the tumour-cell environment. These changes help detect both malignant tumours and early precancerous lesions – adenomas.
Evaluates DNA methylation markers characteristic of colorectal cancer
Detects both cancer and precancerous lesions (adenomas)
Can be performed at home – no doctor’s visit required
Caring for colorectal health – without discomfort or clinic visits
Colotect 1.0 makes it simple and reliable to assess colorectal cancer risk without leaving home. This modern test helps detect both malignant tumours and precancerous lesions at an early stage – when treatment is most effective.
A non-invasive test without discomfort
The stool sample is collected independently at home – no pain and no invasive procedures.
High sensitivity and specificity
88% sensitivity for detecting colorectal cancer and 92% specificity – a reliable tool for risk assessment.
Detecting adenomas before cancer develops
The test detects adenomas (benign lesions that can progress to cancer) with 46% sensitivity.
Avoiding unnecessary visits
A negative result reduces the need to visit a healthcare facility, while a positive result supports timely next steps.
When and for whom is the test recommended?
For people over 50 years of age
Colorectal cancer risk increases significantly with age – this test helps assess it in time and without discomfort.
For individuals with a family history of colorectal cancer
Heredity is an important risk factor – the test helps identify potential risk early.
For those without symptoms who still want to get screened
The disease often develops without signs – Colotect 1.0 can detect it at an early stage.
For those with digestive issues or other bowel complaints
If you have symptoms of unclear origin, this test can be a first step toward answers and further action.
Colotect 1.0 reliability: accuracy and quality metrics
Colotect 1.0 is a clinically validated colorectal cancer test based on DNA methylation analysis. It offers high sensitivity and specificity to reliably detect both cancer and precancerous changes.
88% sensitivity for colorectal cancer
92% specificity for non-advanced neoplasia
46% sensitivity for detecting adenomas (precancerous lesions)
Early colorectal cancer detection
Get tested with Colotect 1.0 and screen without a doctor’s visit.
For Specialists
All key information in one place – from the genes analysed to test accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
For metastatic colorectal cancer, five-year survival is only 6.6%, whereas in early-stage disease it can reach up to 90%. Unfortunately, only about 40% of cases are diagnosed in time. Therefore, patient-friendly methods that promote early detection are vital not only for prognosis, but also for efficient allocation of healthcare resources.
Colotect 1.0 is based on analysing epigenetic changes – DNA methylation – in a stool sample. It evaluates methylation changes in the SDC2, ADHFE1, and PPP2R5C genes, which are characteristic of colorectal tumour processes. The test is performed using methylation-sensitive real-time PCR technology.
Colotect 1.0 sensitivity for detecting stage 0–IV colorectal cancer is 84.8%, with 98% specificity. By comparison, iFOBT sensitivity for detecting early stages is only 60.7%, while Colotect 1.0 reaches 82.1% – supporting more effective detection before bleeding begins.
Tumour cells in the intestinal wall proliferate more frequently, are less firmly attached to the basement membrane, and are less prone to apoptosis. As a result, more tumour cells are shed into stool, DNA is better preserved, and epigenetic changes can be detected more effectively – even without signs of bleeding.
Patients can collect a stool sample at home and send it to the laboratory by mail. Results are provided within 10 calendar days. As the test is certified in Lithuania, clinicians can counsel patients using objective diagnostic data.
